Molecular Health GmbH

  • Land: Germany

Nachricht vom 07.05.2019 | 09:00

Molecular Health appoints Christian Meisel, MD, PhD, as Chief Medical Officer

DGAP-News: Molecular Health GmbH / Key word(s): Personnel

07.05.2019 / 09:00
The issuer is solely responsible for the content of this announcement.

Molecular Health appoints Christian Meisel, MD, PhD, as Chief Medical Officer

Heidelberg, Germany - Tuesday, May 7, 2019 - Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome, today announced the appointment of Dr. Christian Meisel as corporate Chief Medical Officer (CMO).

Dr. Meisel comes to Molecular Health with over 25 years of experience in the healthcare sector - including clinical practice and research & development across academia and the biopharmaceutical industry - and more than 10 years in senior pharma leadership roles. As an MD and PhD with additional qualifications in computer science and extensive experience in precision medicine, Dr. Meisel will be responsible for all clinical aspects of Molecular Health's portfolio and development. As a member of the company's leadership, he will also provide strategic direction and leadership in the development of Molecular Health.

Dr. Friedrich von Bohlen, Co-founder and CEO of Molecular Health, said: "We are very pleased to have Dr. Meisel join as our Chief Medical Officer. He not only is an experienced physician but, next to his background in computer science, also brings an extensive track record and expertise in precision medicine across the biopharmaceutical and diagnostics industry. With his broad experience in molecular diagnostics and drug development, he is a perfect addition to our development and commercial teams and will strategically enhance and further sharpen the focus of our offerings to pharma, physicians, providers, payers and the financial industry. The CMO position is key for our growth strategy, and we are happy to have found Christian for this important role at Molecular Health."

Dr. Meisel adds: "I am very much looking forward to joining Molecular Health - a company at the forefront of the digital transformation of medicine and R&D - as a member of the executive team. I will bring my first-hand experience and deep knowledge of the demands of patients and healthcare providers to further improve Molecular Health's innovative solutions to impact patient care, therapeutic and diagnostic product development, and meet the growing needs of the medical community in the digitalization of healthcare."

Dr. Christian Meisel joins Molecular Health from Roche where he served for more than 14 years in numerous senior leadership roles, including Global Head Personalized Healthcare Platform, acting Global Head Translational Medicine Oncology, and Global Head Biomarkers and Translational R&D Innovation. Dr. Meisel is board-certified in Internal Medicine and in Clinical Pharmacology, holds an MD from the Technical University of Munich, and a PhD from Charité Berlin, where he also served as associate professor and leader of a bioinformatics research group.

About Molecular Health
Molecular Health is a data science-focused artificial intelligence computing company enabling and improving decision making in precision medicine for healthcare organizations. The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets and combining them with novel artificial intelligence and machine learning (AI/ML) technologies. For more than a decade, the company has been developing Dataome, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes. Dataome - stand alone or in combination with customer data - enables the unlocking of actionable intelligence at the molecular level to a) improve diagnosis and therapy decisions by physicians and patients; b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations; and c) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation.
For more information, visit

Molecular Health GmbH
Thomas König
Head of Marketing
Media Relations
MC Services AG
Katja Arnold, Eva Bauer, Laurie Doyle
+49-89-210 228 0

07.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this


Der spezialisierte „Bondpicker“: Deutscher Mittelstandsanleihen Fonds

Der offene Rentenfonds investiert hauptsächlich in ausgewählte Anleihen von Unternehmen des deutschen Mittelstands. Das Kernstück des Investment-Ansatzes ist das KFM-Scoring-Modell, das speziell für diesen Mittelstandssektor entwickelt wurde. Durch das sehr erfahrene aktive Fondsmanagement und den bewährten Anlagestil, sollte dem Anleihefonds auch zukünftig eine deutliche Outperformance gegenüber der allgemeinen Entwicklung am Mittelstandsanleihenmarkt gelingen.

News im Fokus

SAP SE: SAP veröffentlicht vorläufige Ergebnisse für das vierte Quartal 2020 sowie Ausblick für 2021

14. Januar 2021, 23:35

Aktuelle Research-Studie

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Hinzufügen Valneva SE

15. Januar 2021